Table 5.
The effect of Ubenimex on the IC50 values and RIs of MKN45/X cells in the presence or absence of pEGFP-N1-CD13 plasmid for 24h.
| Drugs | MKN45/X | MKN45/X + Ubenimex | MKN45/X+ Ubenimex/pEGFP-N1-CD13 | |||
|---|---|---|---|---|---|---|
| IC50(ug/ml) | RI | IC50(ug/ml) | RI | IC50(ug/ml) | RI | |
| 5-fluorouracil | 146.31±0.02 | 7.07±0.01 | 78.14±0.3∗∗ | 3.8±0.2∗ | 131.15±1.1# | 6.58±0.1# |
|
| ||||||
| Cisplatin | 8.43±0.01 | 22.18±0.02 | 3.09±0.1∗∗ | 7.53±0.2∗∗ | 8.04±1.5# | 19.1±0.2# |
|
| ||||||
| Oxaliplatin | 126.22±0.01 | 6.36±0.01 | 65.32±0.3∗∗ | 3.44±0.1∗ | 110.19±1.7# | 5.92±0.1# |
IC50 values and RI were determined by the CCK-8 method. Data are expressed as means ±SD. ∗∗P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without Ubenimex. #P>0.05 versus 5-fluorouracil, oxaliplatin, and cisplatin with the pEGFP-N1-CD13 plasmid stimulation.